BR112015010943A2 - Construtos de fusão hormônio folículo-estimulante (fsh)/domínio lítico e métodos de produção e utilização dos mesmos - Google Patents

Construtos de fusão hormônio folículo-estimulante (fsh)/domínio lítico e métodos de produção e utilização dos mesmos

Info

Publication number
BR112015010943A2
BR112015010943A2 BR112015010943A BR112015010943A BR112015010943A2 BR 112015010943 A2 BR112015010943 A2 BR 112015010943A2 BR 112015010943 A BR112015010943 A BR 112015010943A BR 112015010943 A BR112015010943 A BR 112015010943A BR 112015010943 A2 BR112015010943 A2 BR 112015010943A2
Authority
BR
Brazil
Prior art keywords
fusion constructs
fsh
follicle
production methods
stimulating hormone
Prior art date
Application number
BR112015010943A
Other languages
English (en)
Inventor
Leuschner Carola
Alila Hector
Hansel William
Original Assignee
Univ Louisiana State
Esperance Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State, Esperance Pharmaceuticals Inc filed Critical Univ Louisiana State
Publication of BR112015010943A2 publication Critical patent/BR112015010943A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

CONSTRUTOS DE FUSÃO, SEU USO, COMPOSIÇÃO E UNIDADE DE DOSAGEM COMPREENDENDO O MESMO, MOLÉCULA DE ÁCIDO NUCLEICO, VETOR, CÉLULA HOSPEDEIRA E USO DA MESMA. A presente invenção refere-se a construtos de fusão, métodos de uso dos construtos de fusão e métodos de tratamento de proliferação celular indesejável ou aberrante ou distúrbios hiperproliferativos, como tumores, cânceres, neoplasia e malignidades.
BR112015010943A 2012-11-15 2013-11-14 Construtos de fusão hormônio folículo-estimulante (fsh)/domínio lítico e métodos de produção e utilização dos mesmos BR112015010943A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261726935P 2012-11-15 2012-11-15
PCT/US2013/070093 WO2014078533A1 (en) 2012-11-15 2013-11-14 Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same

Publications (1)

Publication Number Publication Date
BR112015010943A2 true BR112015010943A2 (pt) 2017-08-22

Family

ID=50731688

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015010943A BR112015010943A2 (pt) 2012-11-15 2013-11-14 Construtos de fusão hormônio folículo-estimulante (fsh)/domínio lítico e métodos de produção e utilização dos mesmos

Country Status (11)

Country Link
US (1) US20140161767A1 (pt)
EP (1) EP2920212A4 (pt)
JP (1) JP2016506373A (pt)
KR (1) KR20150122625A (pt)
CN (1) CN105073779A (pt)
AU (1) AU2013344701A1 (pt)
BR (1) BR112015010943A2 (pt)
CA (1) CA2910311A1 (pt)
HK (1) HK1213923A1 (pt)
IL (1) IL238654A0 (pt)
WO (1) WO2014078533A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518446A (ja) * 2005-12-07 2009-05-07 メダレックス インコーポレーティッド Ｃｔｌａ−４抗体投与量漸増レジメン
KR20210090298A (ko) 2012-10-30 2021-07-19 에스퍼란스 파마슈티컬스, 인코포레이티드 항체/약물 컨쥬게이트 및 이의 사용 방법
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN114150018A (zh) 2014-10-02 2022-03-08 威斯塔解剖学和生物学研究所 治疗癌症的方法和组合物
WO2016073456A1 (en) * 2014-11-04 2016-05-12 The Trustees Of The University Of Pennsylvania Methods and compositions of a follicle stimulating hormone receptor immunoreceptor or chimeric antigen receptor
IT201600101852A1 (it) * 2016-10-11 2018-04-11 Abresearch Srl Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia dei tumori
IT201600101870A1 (it) * 2016-10-11 2018-04-11 Abresearch Srl Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia del neuroblastoma
JP7226803B2 (ja) * 2016-10-11 2023-02-21 オンコグリーン セラピューティクス エッセア 腫瘍の診断及び治療におけるｆｓｈホルモン受容体のリガンド
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN109957580A (zh) * 2019-05-07 2019-07-02 西北农林科技大学 一种表达人促卵泡生长激素（fsh）的方法
BR112022018994A2 (pt) * 2020-03-26 2022-11-29 A28 Therapeutics Inc Construtos de fusão de domínio lítico, inibidores de via de sinalização e métodos de produzir e usar os mesmos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US20050287120A1 (en) * 1997-03-21 2005-12-29 Fisher Paul B Cancer - targeted viral vectors
US7122181B2 (en) * 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
WO2004042015A2 (en) * 2002-11-01 2004-05-21 Mayo Foundation For Medical Education And Research Methods and vectors for controlling gene expression
CA2713126C (en) * 2008-01-24 2017-08-15 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same
WO2010045002A2 (en) * 2008-09-26 2010-04-22 Tocagen Inc. Gene therapy vectors and cytosine deaminases
WO2012050892A2 (en) * 2010-09-29 2012-04-19 Esperance Pharmaceuticals, Inc. Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors

Also Published As

Publication number Publication date
EP2920212A1 (en) 2015-09-23
EP2920212A4 (en) 2016-07-27
US20140161767A1 (en) 2014-06-12
WO2014078533A1 (en) 2014-05-22
HK1213923A1 (zh) 2016-07-15
AU2013344701A1 (en) 2015-05-28
JP2016506373A (ja) 2016-03-03
KR20150122625A (ko) 2015-11-02
IL238654A0 (en) 2015-06-30
CN105073779A (zh) 2015-11-18
CA2910311A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
BR112015010943A2 (pt) Construtos de fusão hormônio folículo-estimulante (fsh)/domínio lítico e métodos de produção e utilização dos mesmos
BR112015009752A2 (pt) conjugados de anticorpo/fármaco e métodos de uso
CY1118899T1 (el) Ενωσεις ενεδιυνης, συζευγματα εξ’ αυτων, και χρησεις και μεθοδοι δια τουτων
CL2015001649A1 (es) Dispersion solida fisicamente estable del acido 4-{[(2r,3s,4r,5s)-4-(4-cloro-2-fluorofenil)-4-ciano-5-(2,2-dimetilpropil)-pirrolidin-2-carbonil]-amino}-3-metoxibenzoico; formulacion solida; metodo de preparacion; preparacion farmaceutica; uso para tratar el cancer, en particular leucemia mieloide aguda o cancer de prostata.
TR201819138T4 (tr) FGFR Kinaz Modülatörleri Olarak Faydalı Kinoksalin Türevleri
MX2014009751A (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
BRPI0906404B8 (pt) construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígeno
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
CL2015001353A1 (es) Molécula que contiene el dominio de fibronectina de tipo iii (fn3) biespecífico, donde el primer dominio se une al receptor del factor de crecimiento epidérmico (egrf) y el segundo al factor de crecimiento de hepatocitos (c-met); dominio de fn3; polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica que la comprende; y uso para tratar el cáncer.
NZ731797A (en) Dna-pk inhibitors
CU20120042A7 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
BR112016005802A2 (pt) conjugados de clorotoxina e métodos de seu uso
BR112012021406A8 (pt) Processos para a síntese dos compostos de diariltioidantoína e diarilidantoína
BR112017021929A2 (pt) derivados de quinolina como inibidores tam rtk, composição farmacêutica compreendendo os referidos derivados e uso destes
PH12014502179B1 (en) Ang2-binding molecules
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
BR112015032542A2 (pt) peptídeos e peptídeos miméticos em tratamentos e usos de combinação para subpopulações de pacientes com câncer
NZ715177A (en) Anti-vegf antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same
PH12016500092B1 (en) New azabenzimidazole derivatives
MX2018006953A (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer.
MX2016007989A (es) Derivados de oxindol, preparacion de los mismos y uso terapeutico en el tratamiento de enfermedades relacionadas con ampk.
CL2014001959A1 (es) Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer.
BR112018076389A2 (pt) composto, método para preparação de um composto, e, composição farmacêutica.
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2540 DE 10-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.